Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...

SOUTH JORDAN, Utah, March 10, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced enrollment of the first patient in its ...

Twice as many preemies treated with drugs for patent ductus arteriosus died compared to those placed under observation Side effects of drug treatments might have unintended consequences for preemies, ...

The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), the first medical device to treat patent ductus arteriosus (PDA) in premature babies weighing as little ...

Merit Medical Systems, Inc. MMSI, on Monday, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus ...

It might be best to do nothing at all to treat a common heart defect among premature newborns Twice as many preemies treated with drugs for patent ductus arteriosus died compared to those placed under ...